FONT-SIZE Plus   Neg

PROLOR Begins Phase II Trial Of Long-Acting Human Growth Hormone In Children

PROLOR Biotech, Inc. (PBTH) said it initiated a Phase II clinical trial of its long-acting CTP-modified version of human growth hormone, or hGH-CTP, in children with growth hormone deficiency.

According to the company, the pediatric hGH-CTP Phase II trial is a randomized, open-label, dose-finding study to evaluate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamic properties of hGH-CTP injected weekly in children with growth hormone deficiency.

The company said the trial will compare the 12-month growth velocity of children receiving certain doses of hGH-CTP, injected once weekly, or commercial hGH injected daily, which is the current standard of care. The trial is expected to take place at up to 35 sites in 12 countries.

The pediatric trial follows successful completion of a Phase II trial of hGH-CTP in growth hormone deficient adults, which demonstrated that hGH-CTP was safe and well tolerated with the potential to reduce the required dosing frequency of human growth hormone from the current standard of one injection per day to a single weekly injection. A subsequent pilot study suggested that bi-monthly dosing of hGH-CTP may also be feasible.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Reynolds American Inc. (RAI) on Friday confirmed that British American Tobacco plc (BATS.L, BTI) has offered to buy the remaining 57.8 percent stake that it does not own in the US tobacco company for $47 billion. Reynolds said its board of directors will evaluate the offer, and respond accordingly to BAT, which currently owns 42.2 percent stake in Reynolds. The proposal represents an enterprise va Fast food giant McDonald's Corp. on Friday reported a 3 percent decline in profit for the third quarter from last year, reflecting one-time charges and lower sales. However, both revenue and earnings per share beat analysts' expectations. Shares of the company are gaining more than 3 percent in pre-market activity. General Electric Company (GE) reported that its third-quarter Industrial operating plus Verticals earnings, a non-GAAP measure, decreased 2% year-over-year to $2.87 billion. Industrial operating plus Verticals earnings per share was $0.32 compared to $0.29 prior year. On average, 15 analysts polled by...
comments powered by Disqus
Follow RTT